‘We’re not bashing our heads on the wall’: Pacific Edge CEO

“We’re not bashing on head on the wall,” said Peter Meintjes, CEO of listed cancer diagnostics company Pacific Edge which is in a trading halt until Tuesday after announcing a $20 million capital raise.

He’s referring to the company seeking recoverage of its Cxbladder detection tests

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).

View terms and conditions.

Individual

Group membership

NBR Marketplace

Smartphone Only Subscription

NZ$29.95 / monthly

Monthly Premium Online Subscription

NZ$49.95 / monthly

Smartphone Only Annual Subscription

NZ$299.00 / yearly

Yearly Premium Online Subscription

NZ$499.00 / yearly

Premium Group Membership 10 Users

NZ$385+GST / monthly

$38.5 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$660+GST / monthly

$33 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1375+GST / monthly

$27.5 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$2100+GST / monthly

$21 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$999.00 / yearly

Already have an account? Login

Fiona Rotherham Fri, 30 May 2025

Contact the Writer: fiona@nbr.co.nz

News tip? Question? Typo? Let us know: editor@nbr.co.nz

Categories

Analysis

Featured